文献速递浆细胞疾病

伴1q获得/扩增的多发性骨髓瘤通过白细胞介素-6受体过表达降低CD38表达

Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.
PubMed 文献 · Br J Haematol · 2025-04-22

该研究探讨伴1q21获得/扩增(1q+)的多发性骨髓瘤(MM)对达雷妥尤单抗耐药机制。结果显示1q+ MM患者CD38表达显著低于1q野生型(WT)MM,且1q+ MM的IL6R表达显著高于1q WT MM。IL-6处理可下调1q+细胞系和原代骨髓样本的CD38并上调磷酸化STAT3,而芦可替尼或托珠单抗抑制IL-6/JAK/STAT通路可恢复CD38表达。

要点

  • 1q+ MM患者CD38表达显著低于1q WT MM患者。
  • 1q+ MM的IL6R表达显著高于1q WT MM,1q+细胞系IL6R水平也更高。
  • 芦可替尼或托珠单抗抑制IL-6/JAK/STAT通路可恢复1q+细胞系和骨髓样本CD38表达。

核心结论

  • 1q+ MM通过IL6R过表达及IL-6/JAK/STAT通路激活下调CD38表达,这解释了达雷妥尤单抗耐药机制,并为未来治疗策略提供思路。

研究设计与样本

  • 研究比较1q+ MM与1q WT MM患者及人骨髓瘤细胞系(HMCLs)的CD38和IL6R表达,并用IL-6处理及芦可替尼或托珠单抗干预验证通路。

主要发现

  • 1q+ MM患者CD38表达显著低于1q WT MM患者。
  • 1q+ MM患者IL6R表达显著高于1q WT MM患者,1q+ HMCLs的IL6R水平也高于1q WT HMCLs。
  • IL-6处理下调1q+ HMCLs和原代骨髓样本的CD38表达,但不下调1q WT HMCLs和骨髓样本的CD38表达。
  • IL-6上调1q+ HMCLs的磷酸化STAT3,但不上调1q WT HMCLs的磷酸化STAT3。
  • 芦可替尼或托珠单抗抑制IL-6/JAK/STAT通路可恢复1q+ HMCLs和骨髓样本的CD38表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab. We aimed to explore the mechanism of daratumumab resistance in 1q+ MM. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM. Next, we focused on the interleukin-6 receptor (IL6R) located in the 1q21 region because a previous report shows that interleukin-6 (IL-6) reduces CD38 expression via the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway activation in MM. Indeed, IL6R expression was significantly higher in 1q+ MM than in 1q WT MM. We verified that the 1q+ human myeloma cell lines (HMCLs) expressed higher IL6R levels than the 1q WT HMCLs. IL-6 treatment induced CD38 downregulation in both the 1q+ HMCLs and primary bone marrow (BM) samples but not in their 1q WT HMCLs and BM samples. IL-6 also resulted in the upregulation of phosphorylated STAT3 in 1q+ HMCLs but not in the 1q WT HMCLs. Furthermore, inhibition of the IL-6/JAK/STAT pathway by treatment with ruxolitinib or tocilizumab restored CD38 expression in the 1q+ HMCLs and BM samples. These findings elucidate the mechanisms underlying daratumumab resistance in 1q+ MM and provide insights for future therapeutic strategies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kuroki W, Kitadate A, Takahashi Y, et al. Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression. Br J Haematol. 2025. PMID: 40259818. doi:10.1111/bjh.20106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。